Dahm AE - Search Results

1

Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.

Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N. Tinholt M, et al. Among authors: dahm ae. BMC Cancer. 2014 Nov 19;14:845. doi: 10.1186/1471-2407-14-845. BMC Cancer. 2014. PMID: 25407022 Free PMC article.

2

Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF-κB and apoptosis mediated by a caspase-3 independent pathway.

Skretting G, Iversen N, Myklebust CF, Dahm AE, Sandset PM. Skretting G, et al. Among authors: dahm ae. Mol Biol Rep. 2012 Dec;39(12):10089-96. doi: 10.1007/s11033-012-1882-7. Epub 2012 Aug 30. Mol Biol Rep. 2012. PMID: 22932941

3

Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms.

Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Jacobsen AF, et al. J Thromb Haemost. 2010 Nov;8(11):2443-9. doi: 10.1111/j.1538-7836.2010.04038.x. J Thromb Haemost. 2010. PMID: 20735725 Free article.

4

Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.

Dahm A, Rosendaal FR, Andersen TO, Sandset PM. Dahm A, et al. Br J Haematol. 2006 Feb;132(3):333-8. doi: 10.1111/j.1365-2141.2005.05876.x. Br J Haematol. 2006. PMID: 16409298 Free article.

5

Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis.

Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Dahm A, et al. Blood. 2003 Jun 1;101(11):4387-92. doi: 10.1182/blood-2002-10-3188. Epub 2003 Jan 30. Blood. 2003. PMID: 12560220 Free article.

6

Mechanisms of thrombosis related to hormone therapy.

Sandset PM, Høibraaten E, Eilertsen AL, Dahm A. Sandset PM, et al. Thromb Res. 2009;123 Suppl 2:S70-3. doi: 10.1016/S0049-3848(09)70015-5. Thromb Res. 2009. PMID: 19217481

7

Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study.

Iversen PO, Dahm A, Skretting G, Mowinckel MC, Stranda A, Østerud B, Sandset PM, Kostovski E. Iversen PO, et al. Thromb Haemost. 2015 Nov;114(5):964-8. doi: 10.1160/TH15-05-0396. Epub 2015 Jul 23. Thromb Haemost. 2015. PMID: 26202881 Clinical Trial.

8

Angiogenesis and hemostasis in hematological neoplasias.

Negaard H, Dahm A, Sandset PM, Iversen PO, Østenstad B. Negaard H, et al. Curr Drug Targets. 2005 Sep;6(6):683-99. doi: 10.2174/1389450054863699. Curr Drug Targets. 2005. PMID: 16178801 Review.

9

Normalization of disrupted clock gene expression in males with tetraplegia: a crossover randomized placebo-controlled trial of melatonin supplementation.

Kostovski E, Frigato E, Savikj M, Dahm A, Sandset PM, Mowinckel MC, Skretting G, Østerud B, Bertolucci C, Iversen PO. Kostovski E, et al. Spinal Cord. 2018 Nov;56(11):1076-1083. doi: 10.1038/s41393-018-0176-x. Epub 2018 Jul 9. Spinal Cord. 2018. PMID: 29985456 Clinical Trial.

10

Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.

Prebensen C, Trøseid M, Ueland T, Dahm A, Sandset PM, Aaberge I, Waalen K, Dyrhol-Riise AM, Taskén K, Kvale D. Prebensen C, et al. PLoS One. 2017 May 2;12(5):e0176527. doi: 10.1371/journal.pone.0176527. eCollection 2017. PLoS One. 2017. PMID: 28464042 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page